Skip to content

Gastric Ultrasound Assessment for Patients Taking GLP1 Agonists

Assessment of Preoperative Gastric Content With Ultrasound in Patients Taking GLP1 Agonists

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06003985
Enrollment
354
Registered
2023-08-22
Start date
2023-08-29
Completion date
2025-02-01
Last updated
2025-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Ultrasound, Glucagon-like Peptide 1, Point of Care Ultrasound

Keywords

GLP1, gastric ultrasound

Brief summary

The aim of this study is to perform bedside gastric point of care ultrasound (POCUS) exams to assess the gastric volume and content (clear liquids vs solid food) perioperatively in patients who take glucagon-like peptide 1 (GLP-1) agonist medications compared to patients who do not take GLP-1 agonists.

Detailed description

Glucagon-like peptide 1 (GLP-1) agonists have existed since 2005, however the newer once-weekly injectable medications particularly semaglutide, and tirzepatide have exploded in popularity due to their weight loss potential. Anesthesiologists nationally have seen an increase in perioperative complications amongst patients taking these medications due to delayed gastric emptying increasing the risk of aspiration in the perioperative period. At HSS the majority of our anesthetics are done under sedation and therefore would not protect the patient from aspiration in the event of vomiting. Protecting patients from aspiration secondary to vomiting during induction or maintenance of anesthesia has always been an important goal to make anesthesia safer leading to the development of NPO guidelines which are intended to protect against the presence of gastric content during anesthetic care. However there is growing concern that patients taking GLP-1 agonists may not be adequately protected using the current nothing by mouth or NPO guidelines. Up to this day there is no literature on how much gastric emptying is delayed during the use of GLP1 following the standard NPO guidelines. Recently Gastric Ultrasound (GUS) has been introduced as a bedside tool for assessing a patients stomach contents and for the risk of aspiration. Gastric ultrasound can identify an empty stomach, a stomach filled with clear liquids, thick liquids or solid food content. If a stomach has clear liquid the volume can be calculated accurately. Generally a stomach with solid or thick liquid content or with clear liquid measuring more than 1.5 ml/kg body weight is considered a full stomach. As GUS is noninvasive and well tolerated, it offers the perfect solution to assessing patient risk in the preoperative period.

Interventions

A gastric ultrasound is a simple, fast, non-invasive bedside diagnostic test that provides a qualitative and quantitative assessment of gastric contents. There are no known risks of a gastric ultrasound exam.

Sponsors

Hospital for Special Surgery, New York
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* GLP 1 patient group: any patient on GLP1 agonists that are dosed once per week (semaglutide, dulaglutide, tirzepatide), for all indications. * Control group (No GLP 1 patients): any patient not on GLP1 agonists that are dosed once per week, for all indications.

Exclusion criteria

* patient refusal to participate * patients with gastric bypass or any other gastric surgery * large hiatal hernia * patients with large ascites * patients on peritoneal dialysis * emergency surgery * pre-existing diagnosis of gastroparesis

Design outcomes

Primary

MeasureTime frameDescription
incidence of delayed gastric emptyingThis will be measured pre-operatively in the holding room area.delayed gastric emptying is defined by the presence of either solid food, thick liquids or a specific volume (\>1.5 ml/kg) of clear liquids on gastric ultrasound.

Secondary

MeasureTime frameDescription
Nothing by mouth (NPO) intervalsThis will be measured pre-operatively in the holding room area.Measure the NPO interval after last solid, liquids, and clears precisely for a subgroup analysis.
Presence of gastric peristalsisThis will be measured pre-operatively in the holding room area.Gastric peristalsis will be graded as present/ absent on gastric ultrasound

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026